Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Cash & Equivalents (2016 - 2025)

Amicus Therapeutics' Cash & Equivalents history spans 16 years, with the latest figure at $214.0 million for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Equivalents changed 0.12% year-over-year to $214.0 million, compared with a TTM value of $214.0 million through Dec 2025, changed 0.12%, and an annual FY2025 reading of $214.0 million, changed 0.12% over the prior year.
  • Cash & Equivalents for Q4 2025 was $214.0 million at Amicus Therapeutics, up from $190.6 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $385.9 million in Q3 2021, with the low at $148.8 million in Q4 2022.
  • Average Cash & Equivalents over 5 years is $219.1 million, with a median of $212.5 million recorded in 2023.
  • Year-over-year, Cash & Equivalents surged 83.21% in 2021 and then crashed 39.31% in 2022.
  • Tracing FOLD's Cash & Equivalents over 5 years: stood at $245.2 million in 2021, then plummeted by 39.31% to $148.8 million in 2022, then skyrocketed by 65.98% to $247.0 million in 2023, then fell by 13.46% to $213.8 million in 2024, then rose by 0.12% to $214.0 million in 2025.
  • Per Business Quant, the three most recent readings for FOLD's Cash & Equivalents are $214.0 million (Q4 2025), $190.6 million (Q3 2025), and $158.7 million (Q2 2025).